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Abstract 
This study tested the applicability of the Individual and Family Self-Management Theory 
(IFSMT) to self-management (SM) in patients with left ventricular assist devices (LVADs).  
From an existing data set, we extracted the following variables that correspond to IFSMT’s 
conceptual dimensions: anxiety, depression, and cognition [context dimension]; self-efficacy 
[SM process dimension]; adherence and quality of life (QOL) [outcome dimensions]. 
Descriptive statistics and partial least squares path modeling procedures were used for data 
analyses. A total of 100 patients (mean age 52 ± 13.4 years) with continuous flow LVAD 
designs comprised the present study. Most patients were White (78%), married (69%), 
college-educated (72%), and on disability (53%). Their mean anxiety and depression scores 
were slightly above normal, while their cognitive function scores were slightly lower than 
normal. LVAD care self-efficacy, adherence, and QOL were within normal ranges. Factor 
loadings ranged from .50 to 1.0, and there were significant forward path relationships 
among the context, process, and outcome dimensions (β ranges from .02 to .60, all p 
values < .05). In conclusion, the IFSMT provides a good fit for SM in LVAD. Further 
research is needed to clarify how best to improve LVAD SM practice and treatment 
outcomes. 
Key w rds:   left-ventricular assist devices, circulatory support, self-management,  
self-management theory, self-management of implantable artificial organs 
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ADVANCING THE SCIENCE OF SELF-MANAGEMENT IN ADULTS WITH LONG-TERM 
LEFT VENTRICULAR ASSIST DEVICES 
  Background  
Over the past two decades, the survival and quality of life (QOL) of patients suffering 
from advanced heart failure have been remarkably improved by implantable left ventricular 
assist devices (LVADs).
 
This improvement in outcomes was attributed in part to the 
advancements in technology, surgical techniques, and post-operative management.
1,2 
However, despite the miniaturization and simplification of LVAD designs, the self-
management (SM) of the LVAD care regimen post hospital discharge is still excessively 
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complex for many patients.
3
 The LVAD care regimen consists of several tasks and 
procedures performed by patients on a daily basis to maintain the normal workings of the 
LVAD system, prevent complications, reduce heart failure symptom burden and re-
hospitalization, and to ultimately optimize health and QOL.
3-5  
During the first 6 months post discharge, most patients require assistance from 
family caregivers to manage the LVAD care regimen, as a result of their functional 
restriction, cognitive difficulty, and/or frailty.
3,5 
Enlistment of family caregivers in SM and 
available support from VAD nurses/coordinators
6
 is a healthcare delivery model aligned with 
the contemporary conceptualization of SM in high acuity and chronically ill patients.
7,8 
Studies have shown that nurse-supported SM interventions, along with healthcare provider-
supported SM programs in adults with multiple comorbidities, are associated with improved 
health and QOL, as well as reduced hospital readmission and mortality rates.
8-10
 
SM is a multidimensional construct, interchangeably referred to as “self-care” in the 
mechanical circulatory support literature.
3
 Self-care is conceptually related to SM, but there 
is a growing consensus in the health sciences literature clarifying the distinction between 
the two. Simply defined, self-care is used to describe health promotion and risk reduction 
behaviors (eg, proper nutrition, exercise, and sleep)
 
performed by individuals without 
assistance from family caregivers and/or guidance from licensed healthcare professionals, 
whereas SM is performed by individuals with assistance .
11-13 
Unfortunately, both SM and 
self-care remain understudied in LVAD, despite the customary practice of patients and/or 
family caregivers being held responsible for LVAD care management post hospital 
discharge.
5,14
  
To address the dearth of scientific knowledge of LVAD SM, we identified a theory 
that can be used by scholars and clinicians alike as a guiding framework for LVAD SM 
research and practice. This paper describes both a theory and a study aimed at explicating 
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the conceptual elements or dimensions of the theory in adults with long-term LVADs. Future 
directions and applications of the theory in LVAD SM research and practice are discussed.    
LVAD SM Theoretical Framework 
The Individual and Family Self-Management Theory (IFSMT)
8,15 
is a middle range 
descriptive theory that has been widely used in research involving adults with chronic and 
multiple conditions. The IFSMT describes SM as a complex phenomenon with three distinct 
but interconnected dimensions: context, process, and outcomes (Figure 1).
15
 The context 
dimension describes SM risks and protective factors at the individual or family level. For 
example, cognitive dysfunction, an absence of family caregivers, or lack of social support 
are all considered risk factors of an effective LVAD SM. On the contrary, sufficient LVAD 
care education and competent caregivers are protective factors of LVAD SM. VAD 
nurses/coordinators
6
 can be added as SM protective factors, as they provide continual SM 
support for LVAD care in the out-patient setting.
6
 The process dimension refers to elements 
of SM including self-regulation (eg, health behavior change), self-efficacy, goal-setting, and 
others. Finally, the outcome dimension consists of proximal and distal outcomes. The 
proximal outcome is the actual engagement (eg, treatment adherence) or direct result of the 
SM process, which in turn determines the distal outcomes (eg, QOL).
8,15 
The multidimensional constructs of the IFSMT are organized as a list of concepts 
clustered in each theoretical dimension, shown in Figure 1.
15 
The lines and arrows in this 
figure illustrate the underlying theoretical assumption that if context and/or SM process 
variable(s) is/are changed (eg, interventions at individual and/or family level), then proximal 
and/or distal outcome dimension(s) is/are also expected to change. This assumption is 
supported by causal inference and association studies in adults with complex chronic 
diseases,
8,10,15 
but has yet to be tested in the LVAD population. Thus, we examined the 
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relationships of variables operationalizing theoretical dimensions (context, process, and 
outcome) of the IFSMT in a sample of adults with long-term LVADs.  
Methods 
Study Design and Sample  
We analyzed existing data from a multistage instrumentation study
16
 that received 
Institutional Review Board approval. A total of 189 LVAD patients from various regions of 
the United States participated in the study, completed in 2015. The inclusion and exclusion 
criteria, as well as recruitment, consenting and screening process, and data collection 
procedures employed in the parent study have been published elsewhere.
16
  
Data Management and Analyses 
We i spected the data file of the parent study and extracted socio-demographics 
data, as well as seven variables that are conceptually related to the context, SM process, 
and outcome dimensions of IFSMT. Variables that comprised the context dimension 
included self-ratings of cognitive function (general and executive), anxiety, and depression. 
A single variable, self-efficacy, comprised the SM process dimension, whereas adherence 
and QOL comprised the proximal and distal outcomes dimension, respectively. The 
operational definition, measurement, validity, and reliability of measures used for the study 
variables are summarized in Table 1.
16-20
  
Next, we examined the pattern of missing data from the extracted data set. Of the 
189 participants, 100 LVAD patients had completed the socio-demographics and seven 
study variables data needed for analyses (ie, theoretical testing). Subsequently, the final 
data set (N=100) was analyzed with descriptive and inferential statistical procedures. Partial 
least squares path modeling (PLS-PM)
21 
was used to infer the relationships among the 
IFSMT context, process, and outcome dimensions. Furthermore, we used the bootstrap 
resampling method to estimate the standard deviations of PLS-PM estimates and test the 
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statistical significance of the estimated effect size of the relationship between theoretical 
dimensions, against a significance criterion of .05. As previously reported,
16 
we found no 
significant relationships among socio-demographics (eg, age and gender), clinical (eg, 
LVAD type and indications) and study variables (eg, cognition and anxiety). Thus, socio-
demographics and clinical variables were not included in the PLS-PM analyses.
 
Data were 
analyzed using IBM SPSS 22.0
 
and R 3.4.1 Software.
22,23
 
Results 
Characteristics of the Sample 
The socio-demographic characteristics of the 100 patients in the present study are 
summarized in Table 2. Patient age ranged from 20 to 82 years (mean, 52 ± 13.4 years). 
Most patients were White (78%), male (69%), educated beyond high school (72%), and 
from the Midwestern (28%) region of the US. Additionally, 69% of patients were married, on 
disability (53%), and living with a designated caregiver (88%). Before receiving their LVAD, 
patients lived with heart failure for an average of 8.1 ± 6.6 years. All patients had continuous 
flow LVAD designs, 86% with axial flow and 14% with centrifugal flow. The LVAD 
indications were bridge-to-transplant (70%), destination therapy (22%), and bridge-to-
myocardial recovery (8%) with implant duration ranging from 2 to 74 months (mean 20.1 ± 
15.6 months).  
LVAD SM Variables 
Table 3 shows a descriptive statistics summary characterizing the seven study 
variables. As shown in this table, the LVAD patients’ mean scores of general cognitive 
function and executive function were similar and slightly lower than normative samples.
17
 
Their anxiety and depression respective mean scores were also similar, but were slightly 
Page 7 of 34 Artificial Organs
This article is protected by copyright. All rights reserved.
A
ut
ho
r M
an
us
cr
ip
t
8 
 
higher than normative samples.
18,19
 LVAD care self-efficacy, LVAD care adherence, and 
QOL mean scores were within normal ranges (Table 3).   
Theoretical fit of IFSMT in LVAD SM 
The path diagram shown in Figure 2 is a depiction of the quantified relationships 
among the LVAD SM variables fitted in each dimension of the IFSMT. Results of the PLS-
PM showed the following forward path relationships among IFSMT dimensions: (a) context 
was associated with SM process; (b) SM process was associated with proximal outcome; 
(c) proximal outcome was associated with distal outcome; (d) context was associated with 
proximal outcome; and (e) context was associated with distal outcome. All of these 
relationships were significant with effect sizes ranging from small (β=.02) to large (β=.60).  
All relationships shown in the path diagram (Figure 2) are supported by both p-
values less than .05 in PLS-PM and factor loadings of latent variables associated with 
IFSMT dimensions. The factor loadings of the latent variables associated with the context 
dimension were the following: 50% (general cognition); 52.5% (executive function); 84.1% 
(anxiety); and 84.2% (depression). LVAD care self-efficacy, a latent variable associated with 
the SM process dimension, showed a factor loading of 99.9%. Respective factor loadings 
for LVAD care adherence and QOL, and latent variables associated with proximal and distal 
outcome dimensions, were 99.8% and 100%. 
Discussion 
The results of the present study infer the theoretical fit of the IFSMT in LVAD SM, 
albeit with a small effect (β=.02), of the path relationship between proximal (adherence) and 
distal (QOL) outcome dimensions. We attributed the small effect to the relatively small 
sample size. However, previous research showed a moderately strong correlation between 
LVAD care adherence and QOL (r=.50),
 
and LVAD care adherence was a predictor of 
QOL.
3,24 
Research in adults with chronic diseases also demonstrated the significant 
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relationship between adherence (ie, medication) and QOL.
25
 The moderate effects of the 
relationships we found between context and process (β=.27) and context and proximal 
outcome (β=.15) dimensions concur with much extant findings from other chronic disease 
populations.
8-12,25 
While there is evidence showing the relationships among cognition, 
anxiety, depression (context), self-efficacy (process), and adherence (proximal outcome) in 
chronic diseases and LVADs,
3,24-28
 the relationships among anxiety, depression, and self-
efficacy found in the present study are novel findings.  
The large effects of the path relationships between context and distal outcome (β=-
.54) dimensions and SM process and proximal outcome (β=.60) dimensions are findings 
with notable significance. Perhaps more significant is the inverse relationship between 
context (eg, anxiety) and distal outcome (QOL) dimensions. This finding can be explained 
by the fact that anxiety and depression are highly prevalent in the LVAD population.
29,30
 As 
shown in Table 3, our study patients’ anxiety and depression scores were slightly worse 
than the average score of US adults living with the same condition (anxiety and 
depression).
18
 Remarkably, the coexistence of anxiety and depression, and associated 
negative influences on QOL, are commonly reported in heart failure studies and from data 
derived from the LVAD population.
29-31 
 
The factor loadings for cognitive function (general and executive) further explain the 
inverse relationship between context and distal outcome dimensions. Cognitive dysfunction 
is common in heart failure, and its negative effect on the patient’s QOL is widely known. 
Thus, its presence is routinely assessed for pre LVAD implant.
3
 However, there is a paucity 
of data-based publications involving the cognitive function of adults who are supported by 
continuous flow LVADs. Two research teams reported the high prevalence of cognitive 
dysfunction (impairment) in patients implanted with continuous flow LVADs. They found that 
cognitive impairment is common up to 1-year post LVAD implant, and that such impairment 
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is profound in older adults, aged 70 years and older.
32,33 
Comparatively, our sample is 
relatively younger (10% comprised of patients aged 70 to 82 years). Although we used a 
different measure than other studies,
32,33
 our measures of general cognition and executive 
function (Table 3) of our study patients were still slightly worse than the average score of 
adults in the US with cognitive dysfunction.
19
  
Given the known adverse effects of anxiety, depression, and cognitive dysfunction 
on learning, as well as performing SM tasks accurately and regularly,
3,34
 further
 
research is 
needed to fully examine these contextual variables. Research is also needed to examine 
the degree to which the family (eg, caregiver) and healthcare providers’ (eg, VAD 
coordinators) support affect the individual SM outcomes. This triadic research design is 
crucial to identify the mechanisms or pathways by which the individual SM risk factors can 
be reduced and managed. According to the IFSMT,
8
 a supportive family or social structure 
is an essential “protective factor” of effective SM outcomes. Protective SM factors in LVAD 
can be achieved by the collaborative efforts of patients, family caregivers, and healthcare 
providers. Early assessment and intervention of the individual (eg, anxiety, cognitive 
dysfunction) and family (eg, caregiver competence and confidence) SM risk factors are 
examples of "protective" strategies that can be embedded in mechanical circulatory support 
programs to optimize LVAD SM outcomes. These strategies can be implemented by VAD 
nurses/coordinators, who are responsible for providing long-term care and psycho-
educational support for LVAD patients and caregivers.
6 
It is worth noting that the relationship between process (self-efficacy) and proximal 
outcome (adherence) was the largest (β=.60) among the path coefficients we found in our 
study. This finding is expected due to the relatively high self-efficacy and adherence scores 
(Table 3), which are above the middle point of possible sum scores.
16 
We can infer from our 
data that a higher level of LVAD care adherence is directly influenced by higher LVAD care 
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self-efficacy, parallel to the IFSMT’s assumptions. According to the IFSMT, sufficient 
knowledge, beliefs, and confidence of disease management (self-efficacy) directly affect the 
results of SM behaviors, such as increased engagement (adherence) in following 
prescribed treatment regimens.
8,15
 Designing research to elucidate the causality between 
self-efficacy and adherence in adults with LVADs (bridge-to-heart transplant, destination 
therapy, or bridge-to-myocardial recovery) would be a logical next step to use the IFSMT 
framework to advance LVAD SM science (Table 4).  
Limitations  
The main limitations of our study included secondary data analyses, the concurrent 
observational research design, and the convenient sampling method employed in the parent 
study. The use of self-administered questionnaires, which are a potential source for 
response bias,
16 
further limits the interpretation of the study findings. This is a particular 
issue for self-ratings of cognition as depression and anxiety have been shown to influence 
self-ratings of cognitive impairment.
35 
Furthermore, self-ratings of cognition may not 
correlate with objective ratings of cognition.
36,37
Moreover, 88% of the patients lived with 
their family caregivers (Table 2). Thus, the possibility of caregivers helping patients 
complete the questionnaires cannot be ruled out. Finally, the theoretical fit of the data was 
limited to select conceptual dimensions. Therefore, these limitations prevented us from 
making definitive conclusions and comprehensive empirical support for the IFSMT in LVAD 
SM.  
Future Directions 
Despite the limitations, we hope that our efforts to initiate empirical support on the 
IFSMT will stimulate scholarly dialogue in the mechanical circulatory support community, 
and heighten awareness regarding the current state of the science underpinning the 
customary practice of LVAD SM. To encourage other investigators and clinicians to move 
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the LVAD SM science forward, Table 4 offers several examples of topics that are 
amendable for research and quality/performance improvement studies aimed at advancing 
LVAD SM science and practice. These topics are clustered around the IFSMT dimensions, 
which have been raised in the literature as pertinent variables or factors that may impact 
LVAD SM outcomes.
3-6,14,16,24
 Future studies should address our study’s limitations, as well 
as explore and expand upon our recommendations in Table 4. Since LVAD SM is 
actualized by patients in collaboration with family caregivers and VAD nurses/coordinators,
3-
6,14,16
 triadic longitudinal research designs will be imperative to explicate the caregiver and 
coordinators’ contributions in LVAD SM outcomes. Equally important are large studies 
reflective of the LVAD population characteristics (eg, race and education) in the United 
States covering concepts beyond the present study to establish a solid empirical base and 
generalizability of the application of IFSMT in LVAD SM. 
Conclusion 
Self-rated anxiety, depression, and cognitive dysfunction are individual contextual 
influences of the LVAD SM process (self-efficacy) and outcomes (adherence and QOL). 
Our data provide initial evidence corroborating the multidimensionality of SM defined by 
IFSMT. The IFSMT is a comprehensive framework that can be used for conceptualizing 
research and clinical scholarly work aimed at advancing the science underpinning LVAD 
SM practice. Large mechanistic studies are still needed to move the current LVAD SM 
science from its formative stage to a well-circumscribed knowledge development. The latter 
is foundational to create and test interventions that will form evidence-based SM practice 
guidelines designed for preventing complications, reducing healthcare utilizations, and 
optimizing health and QOL outcomes among adults living with long-term LVADs.   
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  Figure 1: Conceptual elements of the individual and family self-management theory
15 
 
_________________________________________________________________________ 
Note:  Adopted with authors’ permission and the University of Wisconsin-Milwaukee 
College of Nursing 
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Figure 2:   Associations among the context, process, and outcome dimensions of the Individual and Family Self-Management 
Theory 
 
 
 
Note:  *path coefficients, p values < .05; 
+
factor loadings 
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Figure 2:   Path diagram illustrating the aAssociations among the context, process, and outcome dimensions of the Individual and  
 
Family Self-Management Theory (IFSMT) 
 
 
 
Note:  Circles with broken arrows are latent variables (concepts) for each dimension of the IFSMT; solid and broken arrows indicate 
forward associations between variables; *path coefficients significant at the, p values < .05 level (two-tailed); 
+
factor loadings  
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Figure 2:   Path diagram illustrating the associations among the context, process, and outcome dimensions of the Individual and  
 
Family Self-Management Theory (IFSMT) 
 
 
 
Note:  Circles with broken arrows are latent variables (concepts) for each dimension of the IFSMT; solid and broken arrows indicate 
forward associations between variables; *path coefficients significant at the .05 level (two-tailed); 
+
factor loadings  
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Table 1: Study variables measurements and psychometric properties
16-20 
 
IFSMT 
Dimensions 
 
Concept/Variable 
 
Measures, Items and Response 
Scales 
 
Uses and Scores 
 
Reliability and 
Validity 
 
C
o
n
t
e
x
t
 
(
R
i
s
k
 
a
n
d
 
P
r
o
t
e
c
t
i
v
e
 
F
a
c
t
o
r
s
)
 
 
 
General cognitive 
function 
 
 
 
 
Executive  
function 
 
 
PROMIS Applied Cognition Short 
Form – General
17 
• 8 items 
• 5-point response scale: 1 = 
never to 5 = always 
 
PROMIS Applied Cognition Short 
Form – Executive Function
17 
• 8 items 
• 5-point response scale: 1 = 
never to 5 = always 
 
 
Assesses patient’s perceptions of his/her general 
cognitive concerns such as memory and attention. 
 
Higher mean t-score signifies the concept (ie, 
general cognitive function) being measured. 
 
Assesses patient’s perceptions of his/her difficulties 
in applying cognitive abilities to daily tasks such as 
planning and learning.  
 
Higher mean t-score signifies the concept (ie, 
executive function) being measured. 
 
 
Cronbach α = .89 
 
PROMIS Standards 
of Psychometric 
Testing  
 
Chronbach α = .96 
 
PROMIS Standards 
of Psychometric 
Testing 
Anxiety 
 
 
 
 
 
Depression 
 
PROMIS Short Form – Anxiety
18 
• 8 items 
• 5-point response scale: 1 = 
never to 5 = always  
 
 
PROMIS Short Form – 
Depression
19
  
• 8 items 
• 5-point response scale: 1 = 
never to 5 = always 
Assesses the universal symptoms of anxiety such 
as fear, nervousness, and dizziness. 
 
Higher mean t-score signifies more of the concept 
(ie, anxiety) being measured. 
 
Assesses the universal symptoms of depression 
such as feeling worthless and loss of interest. 
 
Higher mean t-score signifies more of the concept 
(ie, anxiety) being measured. 
 
Cronbach α = .94 
 
PROMIS Standards 
of Psychometric 
Testing  
 
Chronbach α = .96 
 
PROMIS Standards 
of Psychometric 
Testing 
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(
T
h
e
 
S
M
 
P
r
o
c
e
s
s
)
  
Self-Efficacy 
 
LVAD Patient Self-Efficacy 
Scale
16 
• 20 items 
•  6-point response scale: 0 = 
not confident at all to 5 = 
extremely confident  
 
Assesses a patient’s knowledge and confidence 
about LVAD care management in home settings.  
 
Higher sum scores indicate greater knowledge and 
confidence in the ability to manage the LVAD home 
care regimen. 
 
Chronbach α = .94 
 
Factor analytics 
 
 
 
 
P
r
o
x
i
m
a
l
 
 
Adherence 
 
LVAD Patient Home 
Management Adherence Scale
16 
• 9 items 
• 6-point response scale: 0 = 
never to 5 = all the time 
 
Assesses the extent to which a patient follows the 
prescribed LVAD care regimen.  
 
Higher sum scores indicate greater adherence to 
LVAD home care regimen.  
 
 
Chronbach α = .94 
 
Factor analytics 
D
i
s
t
a
l
 
 
Quality of  
life 
 
World Health Organization 
Quality of Life (QOL) –BREF
20 
• 26 items 
• 5-point rating scale with 
various responses, eg, 1= 
very poor to 5 = very good or 
1 = very dissatisfied to 5 = 
very satisfied 
 
 
Generic QOL instrument, which assesses physical, 
psychological, social, and environmental domains of 
QOL. 
 
Sum scores of all domains of QOL indicate the 
person’s perception of his/her general or overall 
QOL. Higher sum scores indicate better QOL.  
 
Chronbach α = .90 
 
Factor analytics 
and cross-cultural 
validity 
 
Note: PROMIS - Patient-Reported Outcomes Measurement Information System  
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Table 2: Socio-demographic Characteristics of the Sample 
 
 
Characteristic 
 
n (%)* 
 
 
Characteristic 
 
n (%)* 
 
 
Gender: 
Male 
Female 
Race: 
White 
Black 
Asian   
Mixed 
Native American 
Hisp nic non-white 
Region: 
Northeast 
Midwest 
Southeast 
Southwest 
West 
Education: 
Less than high school 
High school 
Some college 
College and higher 
 
 
69 (69) 
31 (31) 
 
78 (78) 
15 (15) 
2 (2) 
3 (3) 
1 (1) 
1 (1) 
 
25 (25) 
28 (28) 
14 (14) 
11 (11) 
9 (9) 
 
5 (5) 
23 (23) 
43 (43) 
29 (29) 
 
Marital Status: 
Married 
Single  
Divorced 
Employment: 
Full-time 
Part-time 
Retired 
Disability 
Unemployed 
Designated Caregivers: 
Yes 
No  
 
 
 
 
 
 
 
 
 
 
69 (69) 
31 (31) 
8 (8) 
 
15 (15) 
5 (5) 
21 (21) 
53 (53) 
6 (6) 
 
88 (88) 
12 (12) 
 
 
 
 
 
 
 
Note:  *Due to missing data
 
not all percentages total 100 
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 Table 3: Summary statistics of study variables 
 
Measures and Norms 
 
 
Ranges 
 
 
Mean and Standard 
Deviation 
 
 
Cognitive Function – General 
Mean (t): 50 ± 10 
 
 
31 – 59.3 
 
47.4 ± 8.0 
Cognitive Function – Executive 
Mean (t): 50 ± 10 
 
19.5 – 57.6 47.9 ± 8.7 
Anxiety 
Mean (t): 50 ± 10 
 
 
37.1 - 70 
 
52.0 ± 9.0 
Depression 
Mean (t): 50 ± 10 
 
 
38.2 - 72 
 
51 ± 9.3 
LVAD Patient Self-Efficacy 
Sum: 0 to 100  
 
11 – 100 86.76 ± 14.5 
LVAD Patient Home Management 
Adherence 
Sum: 0 to 45 
7 - 45 39.0 ± 6.8 
 
World Health Organization  
Quality of Life-BREF 
Sum: 0 to 100 
 
 
26.5 – 98.5 
 
69.4 ± 16.8 
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Table 4:  Recommendations for future research in LVAD SM guided by the Individual and Family Self-Management Theory 
(IFSMT) 
 
IFSMT 
Dimensions 
 
 
        Concept 
 
Example of researchable topics and questions 
C
o
n
t
e
x
t
 
(
R
i
s
k
 
a
n
d
 
P
r
o
t
e
c
t
i
v
e
 
F
a
c
t
o
r
s
)
 
 
 
Individual factors  
 
 
 
 
 
 
 
 
 
 
 
 
 
Family factors 
 
• Effect of functional capacity, co-morbidities, complications, and re-
hospitalizations on SM. 
 
• Mechanism of the influence or effect of sleep disruptions and excessive 
daytime sleepiness on SM. 
 
• Effect of health literacy on SM process and outcomes. 
 
• How do patient education, competency (LVAD care knowledge and 
skills), and competency reassessments affect SM? (Note: This topic 
should also address the need for using objective measures of cognitive 
function cited in the discussion section in the main text). 
 
 
• What is the impact of family caregiver status (full-time, part-time, live-in, 
or nearby) on SM? 
 
• What are the caregiver characteristics (eg, competency, health literacy, 
caregiving preparedness, and confidence) that are predictive of effective 
SM? 
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P
r
o
c
e
s
s
 
(
T
h
e
 
S
M
 
P
r
o
c
e
s
s
)
 
 
Knowledge and beliefs 
 
 
 
 
 
Self-regulation skills and 
abilities 
 
 
 
 
 
 
 
Social facilitation 
 
• Intervention to optimize LVAD care self-efficacy. 
 
• Explore interventions designed for individual goal setting and outcome 
expectations (eg, goals for managing LVAD flows specific to the device 
and individual). 
 
• Develop and test technology (eg, mobile phone app) that are easy and 
efficient for self-monitoring of LVAD parameters (eg, flow, power) and 
heart failure symptoms, etc., and features that provide feedback and 
coach how to manage abnormal parameters and symptoms. 
 
•  Intervention to address cognitive difficulties, anxiety, and/or depression 
and their impact on SM outcomes (can be classified as 
individual/context SM risk factor). 
 
• Effect of the role of VAD nurses or coordinators (eg, frequent follow up 
and psychoeducational support) on SM outcomes. 
 
• What VAD care team (eg, skill mix) characteristics are predictive of 
effective SM outcomes? 
 
O
u
t
c
o
m
e
 
–
 
 
P
r
o
x
i
m
a
l
 
 
Individual and family self-
management behaviors 
outcomes 
 
 
 
 
Healthcare utilizations 
 
• Intervention to improve adherence on LVAD-specific care, medications, 
diet, and physical activity. 
 
• Apply health promotion, risk reduction, and symptom management 
interventions tested in heart failure patients with cardiac devices (eg, 
pacemakers, defibrillators) or post cardiac surgery. 
 
• Hospital re-admissions 
 
• Unscheduled emergency room and clinic visits 
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O
u
t
c
o
m
e
 
–
 
 
D
i
s
t
a
l
 
 
Health status 
 
 
Quality of life 
 
Cost 
 
• LVAD-specific and related complications, co-morbidity, functional status, 
frailty and mortality. 
 
• Use of generic and LVAD-specific QOLmeasures 
 
• Cost of technology used for LVAD SM and health care providers’ cost 
supporting LVAD SM 
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Table 4:  Recommendations for future research in LVAD SM guided by the Individual and Family Self-Management Theory 
(IFSMT) 
 
IFSMT 
Dimensions 
 
 
        Concept 
 
Example of researchable topics and questions 
C
o
n
t
e
x
t
 
(
R
i
s
k
 
a
n
d
 
P
r
o
t
e
c
t
i
v
e
 
F
a
c
t
o
r
s
)
 
 
 
Individual factors  
 
 
 
 
 
 
 
 
 
 
 
 
 
Family factors 
 
• Effect of functional capacity including frailty, co-morbidities, 
complications, and re-hospitalizations on SM. 
 
• Mechanism of the influence or effect of sleep disruptions and excessive 
daytime sleepiness on SM. 
 
• Effect of health literacy on SM process and outcomes. 
 
• How do patient education, competency (LVAD care knowledge and 
skills), and competency reassessments affect SM? (Note: This topic 
should also address the need for using objective measures of cognitive 
function cited in the discussion section in the main text). 
 
 
• What is the impact of family caregiver status (full-time, part-time, live-in, 
or nearby) on SM? 
 
• What are the caregiver characteristics (eg, competency, health literacy, 
caregiving preparedness, and confidence) that are predictive of effective 
SM? 
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P
r
o
c
e
s
s
 
(
T
h
e
 
S
M
 
P
r
o
c
e
s
s
)
 
 
Knowledge and beliefs 
 
 
 
 
 
Self-regulation skills and 
abilities 
 
 
 
 
 
 
 
Social facilitation 
 
• Intervention to optimize LVAD care self-efficacy. 
 
• Explore interventions designed for individual goal setting and outcome 
expectations (eg, goals for managing LVAD flows specific to the device 
and individual). 
 
• Develop and test technology (eg, mobile phone app) that are easy and 
efficient for self-monitoring of LVAD parameters (eg, flow, power) and 
heart failure symptoms, etc., and features that provide feedback and 
coach how to manage abnormal parameters and symptoms. 
 
•  Intervention to address cognitive difficulties, anxiety, and/or depression 
and their impact on SM outcomes (can be classified as 
individual/context SM risk factor). 
 
• Effect of the role of VAD nurses or coordinators (eg, frequent follow up 
and psychoeducational support) on SM outcomes. 
 
• What VAD care team (eg, skill mix) characteristics are predictive of 
effective SM outcomes? 
 
O
u
t
c
o
m
e
 
–
 
 
P
r
o
x
i
m
a
l
 
 
Individual and family self-
management behaviors 
outcomes 
 
 
 
 
Healthcare utilizations 
 
• Intervention to improve adherence on LVAD-specific care, medications, 
diet, and physical activity. 
 
• Apply health promotion, risk reduction, and symptom management 
interventions tested in heart failure patients with cardiac devices (eg, 
pacemakers, defibrillators) or post cardiac surgery. 
 
• Hospital re-admissions 
 
• Unscheduled emergency room and clinic visits 
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O
u
t
c
o
m
e
 
–
 
 
D
i
s
t
a
l
 
 
Health status 
 
 
Quality of life 
 
Cost 
 
• LVAD-specific and related complications, co-morbidity, functional status, 
frailty and mortality. 
 
• Use of generic and LVAD-specific QOLmeasures 
 
• Cost of technology used for LVAD SM and health care providers’ cost 
supporting LVAD SM 
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Table 4:  Recommendations for future research in LVAD SM guided by the Individual and Family Self-Management Theory 
(IFSMT) 
 
IFSMT 
Dimensions 
 
 
        Concept 
 
Example of researchable topics and questions 
C
o
n
t
e
x
t
 
(
R
i
s
k
 
a
n
d
 
P
r
o
t
e
c
t
i
v
e
 
F
a
c
t
o
r
s
)
 
 
 
Individual factors  
 
 
 
 
 
 
 
 
 
 
 
 
 
Family factors 
 
• Effect of functional capacity including frailty, co-morbidities, 
complications, and re-hospitalizations on SM. 
 
• Mechanism of the influence or effect of sleep disruptions and excessive 
daytime sleepiness on SM. 
 
• Effect of health literacy on SM process and outcomes. 
 
• How do patient education, competency (LVAD care knowledge and 
skills), and competency reassessments affect SM? (Note: This topic 
should also address the need for using objective measures of cognitive 
function cited in the discussion section in the main text). 
 
 
• What is the impact of family caregiver status (full-time, part-time, live-in, 
or nearby) on SM? 
 
• What are the caregiver characteristics (eg, competency, health literacy, 
caregiving preparedness, and confidence) that are predictive of effective 
SM? 
 
Page 32 of 34Artificial Organs
56
57
58
59
60
This article is protected by copyright. All rights reserved.
Au
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
2 
P
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(
T
h
e
 
S
M
 
P
r
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s
)
 
 
Knowledge and beliefs 
 
 
 
 
 
Self-regulation skills and 
abilities 
 
 
 
 
 
 
 
Social facilitation 
 
• Intervention to optimize LVAD care self-efficacy. 
 
• Explore interventions designed for individual goal setting and outcome 
expectations (eg, goals for managing LVAD flows specific to the device 
and individual). 
 
• Develop and test technology (eg, mobile phone app) that are easy and 
efficient for self-monitoring of LVAD parameters (eg, flow, power) and 
heart failure symptoms, etc., and features that provide feedback and 
coach how to manage abnormal parameters and symptoms. 
 
•  Intervention to address cognitive difficulties, anxiety, and/or depression 
and their impact on SM outcomes (can be classified as 
individual/context SM risk factor). 
 
• Effect of the role of VAD nurses or coordinators (eg, frequent follow up 
and psychoeducational support) on SM outcomes. 
 
• What VAD care team (eg, skill mix) characteristics are predictive of 
effective SM outcomes? 
 
O
u
t
c
o
m
e
 
–
 
 
P
r
o
x
i
m
a
l
 
 
Individual and family self-
management behaviors 
outcomes 
 
 
 
 
Healthcare utilizations 
 
• Intervention to improve adherence on LVAD-specific care, medications, 
diet, and physical activity. 
 
• Apply health promotion, risk reduction, and symptom management 
interventions tested in heart failure patients with cardiac devices (eg, 
pacemakers, defibrillators) or post cardiac surgery. 
 
• Hospital re-admissions 
 
• Unscheduled emergency room and clinic visits 
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O
u
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c
o
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e
 
–
 
 
D
i
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t
a
l
 
 
Health status 
 
 
Quality of life 
 
Cost 
 
• LVAD-specific and related complications, co-morbidity, functional status, 
frailty and mortality. 
 
• Use of generic and LVAD-specific QOLmeasures 
 
• Cost of technology used for LVAD SM and health care providers’ cost 
supporting LVAD SM 
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